ReviewPediatric investigation2026
Atopic dermatitis and attention-deficit/hyperactivity disorder comorbidity in children and adolescents: Epidemiology, mechanisms, and clinical management.
Review in Pediatric investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) and attention-deficit/hyperactivity disorder (ADHD) frequently co-occur in children and adolescents, increasing the disease burden and clinical complexity. Accumulating evidence suggests that children with AD have a higher risk of incident ADHD, a risk that is particularly pronounced in those with early-onset, severe AD, or significant sleep disturbances. The underlying mechanisms are hypothesized to involve the dysregulation of the "inflammation-itching-neurobehavioral" axis. This narrative review synthesizes current evidence regarding the epidemiology, potential mechanisms, and clinical management of this comorbidity. We propose that proactive screening and aggressive control of skin inflammation and pruritus are key to disrupting this vicious cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.